Sökning: WFRF:(Palmer Tom) > (2015-2019) > Comparison of adjuv...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08290naa a2200805 4500 | |
001 | oai:DiVA.org:uu-318923 | |
003 | SwePub | |
008 | 170405s2017 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:135270581 | |
009 | oai:lup.lub.lu.se:0b3ec941-303e-4c06-933f-e471df933297 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3189232 URI |
024 | 7 | a https://doi.org/10.1016/S0140-6736(16)32409-62 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1352705812 URI |
024 | 7 | a https://lup.lub.lu.se/record/0b3ec941-303e-4c06-933f-e471df9332972 URI |
040 | a (SwePub)uud (SwePub)kid (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Neoptolemos, John P.u Univ Liverpool, Liverpool, Merseyside, England.;Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.,University of Liverpool4 aut |
245 | 1 0 | a Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) :b a multicentre, open-label, randomised, phase 3 trial |
264 | 1 | c 2017 |
338 | a electronic2 rdacarrier | |
520 | a Background: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcitabine and capecitabine than with gemcitabine alone in advanced or metastatic pancreatic cancer. We aimed to determine the efficacy and safety of gemcitabine and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer.Methods: We did a phase 3, two-group, open-label, multicentre, randomised clinical trial at 92 hospitals in England, Scotland, Wales, Germany, France, and Sweden. Eligible patients were aged 18 years or older and had undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas (R0 or R1 resection). We randomly assigned patients (1: 1) within 12 weeks of surgery to receive six cycles of either 1000 mg/m(2) gemcitabine alone administered once a week for three of every 4 weeks (one cycle) or with 1660 mg/m(2) oral capecitabine administered for 21 days followed by 7 days' rest (one cycle). Randomisation was based on a minimisation routine, and country was used as a stratification factor. The primary endpoint was overall survival, measured as the time from randomisation until death from any cause, and assessed in the intention-to-treat population. Toxicity was analysed in all patients who received trial treatment. This trial was registered with the EudraCT, number 2007-004299-38, and ISRCTN, number ISRCTN96397434.Findings: Of 732 patients enrolled, 730 were included in the final analysis. Of these, 366 were randomly assigned to receive gemcitabine and 364 to gemcitabine plus capecitabine. The Independent Data and Safety Monitoring Committee requested reporting of the results after there were 458 (95%) of a target of 480 deaths. The median overall survival for patients in the gemcitabine plus capecitabine group was 28.0 months (95% CI 23.5-31.5) compared with 25.5 months (22.7-27.9) in the gemcitabine group (hazard ratio 0.82 [95% CI 0.68-0.98], p=0.032). 608 grade 3-4 adverse events were reported by 226 of 359 patients in the gemcitabine plus capecitabine group compared with 481 grade 3-4 adverse events in 196 of 366 patients in the gemcitabine group.Interpretation: The adjuvant combination of gemcitabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng |
700 | 1 | a Palmer, Daniel H.u Univ Liverpool, Liverpool, Merseyside, England.;Clatterbridge Canc Ctr, Wirral, Merseyside, England.,University of Liverpool4 aut |
700 | 1 | a Ghaneh, Paulau Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.,Royal Liverpool University Hospital4 aut |
700 | 1 | a Psarelli, Eftychia E.u Univ Liverpool, Liverpool, Merseyside, England.,University of Liverpool4 aut |
700 | 1 | a Valle, Juan W.u Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England.,University of Manchester4 aut |
700 | 1 | a Halloran, Christopher M.u Univ Liverpool, Liverpool, Merseyside, England.;Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.,University of Liverpool4 aut |
700 | 1 | a Faluyi, Olusolau Clatterbridge Canc Ctr, Wirral, Merseyside, England.,Clatterbridge Cancer Centre4 aut |
700 | 1 | a O'Reilly, Derek A.u Manchester Royal Infirm, Manchester, Lancs, England.,Manchester Royal Infirmary4 aut |
700 | 1 | a Cunningham, Davidu Royal Marsden Hosp, London, England.,Royal Marsden Hospital, London4 aut |
700 | 1 | a Wadsley, Jonathanu Weston Pk Hosp, Sheffield, S Yorkshire, England.,Weston Park Hospital4 aut |
700 | 1 | a Darby, Suzanneu Weston Pk Hosp, Sheffield, S Yorkshire, England.4 aut |
700 | 1 | a Meyer, Timu Royal Free Hosp, London, England.4 aut |
700 | 1 | a Gillmore, Roopinderu Royal Free Hosp, London, England.4 aut |
700 | 1 | a Anthoney, Alanu St James Univ Hosp, Leeds, W Yorkshire, England.4 aut |
700 | 1 | a Lind, Pehru Karolinska Institutet4 aut |
700 | 1 | a Glimelius, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)bengglim |
700 | 1 | a Falk, Stephenu Bristol Haematol & Oncol Ctr, Bristol, Avon, England.4 aut |
700 | 1 | a Izbicki, Jakob R.u Univ Hamburg, Med Inst UKE, Hamburg, Germany.4 aut |
700 | 1 | a Middleton, Gary Williamu Royal Surrey Cty Hosp, Guildford, Surrey, England.4 aut |
700 | 1 | a Cummins, Sebastianu Royal Surrey Cty Hosp, Guildford, Surrey, England.4 aut |
700 | 1 | a Ross, Paul J.u Guys Hosp, London, England.4 aut |
700 | 1 | a Wasan, Harpreetu Hammersmith Hosp, London, England.4 aut |
700 | 1 | a McDonald, Alecu Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland.4 aut |
700 | 1 | a Crosby, Tomu Velindre Hosp, Cardiff, S Glam, Wales.4 aut |
700 | 1 | a Ma, Yuk Tingu Queen Elizabeth Hosp, Birmingham, W Midlands, England.4 aut |
700 | 1 | a Patel, Kinnariu Churchill Hosp, Oxford, England.4 aut |
700 | 1 | a Sherriff, Davidu Derriford Hosp, Plymouth, Devon, England.4 aut |
700 | 1 | a Soomal, Rubinu Ipswich Hosp, Ipswich, Suffolk, England.4 aut |
700 | 1 | a Borg, Davidu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)onk-dbo |
700 | 1 | a Sothi, Sharmilau Univ Hosp Coventry, Coventry, W Midlands, England.4 aut |
700 | 1 | a Hammel, Pascalu Hop Beaujon, Clichy, France.4 aut |
700 | 1 | a Hackert, Thilou Heidelberg Univ, Heidelberg, Germany.4 aut |
700 | 1 | a Jackson, Richardu Univ Liverpool, Liverpool, Merseyside, England.4 aut |
700 | 1 | a Buechler, Markus W.u Heidelberg Univ, Heidelberg, Germany.4 aut |
710 | 2 | a Univ Liverpool, Liverpool, Merseyside, England.;Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.b University of Liverpool4 org |
773 | 0 | t The Lancetg 389:10073, s. 1011-1024q 389:10073<1011-1024x 0140-6736x 1474-547X |
856 | 4 | u https://doi.org/10.1016/S0140-6736(16)32409-6y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1087070/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u http://dx.doi.org/10.1016/S0140-6736(16)32409-6x freey FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-318923 |
856 | 4 8 | u https://doi.org/10.1016/S0140-6736(16)32409-6 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:135270581 |
856 | 4 8 | u https://lup.lub.lu.se/record/0b3ec941-303e-4c06-933f-e471df933297 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy